These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36574772)

  • 21. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors.
    Mor M; Werbner M; Alter J; Safra M; Chomsky E; Lee JC; Hada-Neeman S; Polonsky K; Nowell CJ; Clark AE; Roitburd-Berman A; Ben-Shalom N; Navon M; Rafael D; Sharim H; Kiner E; Griffis ER; Gershoni JM; Kobiler O; Leibel SL; Zimhony O; Carlin AF; Yaari G; Dessau M; Gal-Tanamy M; Hagin D; Croker BA; Freund NT
    PLoS Pathog; 2021 Feb; 17(2):e1009165. PubMed ID: 33571304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deep immunoglobulin repertoire sequencing depicts a comprehensive atlas of spike-specific antibody lineages shared among COVID-19 convalescents.
    Yan Q; Zhang Y; Hou R; Pan W; Liang H; Gao X; Deng W; Huang X; Qu L; Tang C; He P; Liu B; Wang Q; Zhao X; Lin Z; Chen Z; Li P; Han J; Xiong X; Zhao J; Li S; Niu X; Chen L
    Emerg Microbes Infect; 2024 Dec; 13(1):2290841. PubMed ID: 38044868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duration of SARS-CoV-2 Serum-Neutralizing Antibodies Against SARS-CoV-2 Dependent on the Individual.
    Li J; Zou L; Li S; Zou R; Fang Z; Zhang P; Li H; Wang S; Ke D; Gao P; Jin C; Fang C; Zhou J; He E; Skog S
    Viral Immunol; 2023 Apr; 36(3):153-162. PubMed ID: 36944125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection.
    Arons E; Henry K; Haas C; Gould M; Tsintolas J; Mauter J; Zhou H; Burbelo PD; Cohen JI; Kreitman RJ
    J Med Virol; 2023 Oct; 95(10):e29179. PubMed ID: 37877800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
    Moriyama S; Adachi Y; Sato T; Tonouchi K; Sun L; Fukushi S; Yamada S; Kinoshita H; Nojima K; Kanno T; Tobiume M; Ishijima K; Kuroda Y; Park ES; Onodera T; Matsumura T; Takano T; Terahara K; Isogawa M; Nishiyama A; Kawana-Tachikawa A; Shinkai M; Tachikawa N; Nakamura S; Okai T; Okuma K; Matano T; Fujimoto T; Maeda K; Ohnishi M; Wakita T; Suzuki T; Takahashi Y
    Immunity; 2021 Aug; 54(8):1841-1852.e4. PubMed ID: 34246326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poorly Expressed Alleles of Several Human Immunoglobulin Heavy Chain Variable Genes are Common in the Human Population.
    Ohlin M
    Front Immunol; 2020; 11():603980. PubMed ID: 33717051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain.
    Anzai I; Fujita J; Ono C; Kosaka Y; Miyamoto Y; Shichinohe S; Takada K; Torii S; Taguwa S; Suzuki K; Makino F; Kajita T; Inoue T; Namba K; Watanabe T; Matsuura Y
    Microbiol Spectr; 2024 Apr; 12(4):e0365523. PubMed ID: 38415660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
    Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
    Front Immunol; 2021; 12():715464. PubMed ID: 34539645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020.
    Zhang S; Ma P; Orzechowski M; Lemmer A; Rzasa K; Bagnall J; Barkho S; Chen M; He L; Neitupski R; Tran V; Ackerman R; Gath E; Bond A; Frongillo G; Cleland T; Golas A; Gaca A; Fitzgerald M; Kelly K; Hazegh K; Dumont L; Hoffman C; Homer M; Marks P; Woolley A; Wong S; Gomez J; Livny J; Hung D
    mBio; 2023 Apr; 14(2):e0352322. PubMed ID: 36786604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class.
    Rapp M; Guo Y; Reddem ER; Yu J; Liu L; Wang P; Cerutti G; Katsamba P; Bimela JS; Bahna FA; Mannepalli SM; Zhang B; Kwong PD; Huang Y; Ho DD; Shapiro L; Sheng Z
    Cell Rep; 2021 Apr; 35(1):108950. PubMed ID: 33794145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination.
    Sariol CAA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina-Rodríguez A; Cruz L; Stone ETT; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AKK; Brien JDD; Espino AMM
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
    Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
    Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.
    Gonzalez Lopez Ledesma MM; Sanchez L; Ojeda DS; Oviedo Rouco S; Rossi AH; Varese A; Mazzitelli I; Pascuale CA; Miglietta EA; Rodríguez PE; Pallarés HM; Costa Navarro GS; Caramelo JJ; Rothlauf PW; Liu Z; Bloyet LM; Cornejo Pontelli M; Rasetto NB; Wenker SD; Ramis LY; Bialer MG; de Leone MJ; Hernando CE; Bianchimano L; Ríos AS; Treffinger Cienfuegos MS; Rodriguez García DR; Longueira Y; Laufer N; Alvarez D; Ceballos A; Ochoa V; Monzani C; Turk G; Salvatori M; Carradori J; Prost K; Rima A; Varela C; Ercole R; Toro RI; Gutierrez S; Zubieta M; Acuña D; Nabaes Jodar MS; Torres C; Mojsiejczuk L; Viegas M; Velazquez P; Testa C; Kreplak N; Yanovsky M; Whelan S; Geffner J; Pifano M; Gamarnik AV
    mBio; 2022 Feb; 13(1):e0344221. PubMed ID: 35073758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.
    Dong J; Zost SJ; Greaney AJ; Starr TN; Dingens AS; Chen EC; Chen RE; Case JB; Sutton RE; Gilchuk P; Rodriguez J; Armstrong E; Gainza C; Nargi RS; Binshtein E; Xie X; Zhang X; Shi PY; Logue J; Weston S; McGrath ME; Frieman MB; Brady T; Tuffy KM; Bright H; Loo YM; McTamney PM; Esser MT; Carnahan RH; Diamond MS; Bloom JD; Crowe JE
    Nat Microbiol; 2021 Oct; 6(10):1233-1244. PubMed ID: 34548634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.
    Schmidt F; Weisblum Y; Rutkowska M; Poston D; DaSilva J; Zhang F; Bednarski E; Cho A; Schaefer-Babajew DJ; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Nature; 2021 Dec; 600(7889):512-516. PubMed ID: 34544114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants.
    Korenkov M; Zehner M; Cohen-Dvashi H; Borenstein-Katz A; Kottege L; Janicki H; Vanshylla K; Weber T; Gruell H; Koch M; Diskin R; Kreer C; Klein F
    Immunity; 2023 Dec; 56(12):2803-2815.e6. PubMed ID: 38035879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
    O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
    Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.